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Abstract: Autophagy, apoptosis, and the unfolded protein response (UPR) are fundamental biological
processes essential for manifold cellular functions in health and disease. Idiopathic pulmonary
fibrosis (IPF) is a progressive and lethal pulmonary disorder associated with aging that has limited
therapies, reflecting our incomplete understanding. We conducted an observational study linking
molecular markers of cell stress response pathways (UPR: BiP, XBP1; apoptosis: cleaved caspase-3;
autophagy: LC3β) in lung tissues from IPF patients and correlated the expression of these protein
markers to each subject’s lung function measures. We hypothesized that changes in lung tissue
expression of apoptosis, autophagy, and UPR markers correlate with lung function deficits in IPF.
The cell stress markers BiP, XBP1, LC3β puncta, and cleaved caspase-3 were found to be elevated
in IPF lungs compared to non-IPF lungs, and, further, BiP and cleaved caspase-3 co-localized in
IPF lungs. Considering lung function independently, we observed that increased XBP1, BiP, and
cleaved caspase-3 were each associated with reduced lung function (FEV1, FVC, TLC, RV). However,
increased lung tissue expression of LC3β puncta was significantly associated with increased diffusion
capacity (DLCO), an indicator of alveolar–capillary membrane function. Similarly, the co-localization
of UPR (XBP1, BiP) and autophagy (LC3β puncta) markers was positively correlated with increased
lung function (FEV1, FVC, TLC, DLCO). However, the presence of LC3β puncta can indicate either
autophagy flux inhibition or activation. While the nature of our observational cross-sectional study
design does not allow conclusions regarding causal links between increased expression of these
cell stress markers, lung fibrosis, and lung function decline, it does provide some insights that are
hypothesis-generating and suggests that within the milieu of active UPR, changes in autophagy
flux may play an important role in determining lung function. Further research is necessary to
investigate the mechanisms linking UPR and autophagy in IPF and how an imbalance in these cell
stress pathways can lead to progressive fibrosis and loss of lung function. We conclude by presenting
five testable hypotheses that build on the research presented here. Such an understanding could
eventually lead to the development of much-needed therapies for IPF.
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1. Introduction
Idiopathic pulmonary fibrosis (IPF) is the most common of the interstitial lung diseases affecting the older population [1,2]. IPF is a progressive and fatal disorder with
a post-diagnosis median survival of 3–5 years [1–3]; there are few options in terms of
available pharmacological therapies. The etiology of IPF remains unknown. However, the
fundamental pathological processes involved in IPF may be triggered by chronic and/or
repetitive damage to the alveolar epithelium of the lung [1,3]. The injured epithelium
results in the activation of other types of lung cells, namely, alveolar fibroblasts. The
resultant wound healing response by the activated fibroblasts leads to the accumulation
of extracellular matrix (ECM), causing phenotypic yet irreversible lung fibrosis that leads
to loss of lung function [1–3]. In addition, aging is increasingly recognized as a very
important factor in the development of IPF, where fibroblast senescence can contribute to
IPF pathogenesis [4].
Macroautophagy (hereafter referred to as “autophagy”), a lysosome-mediated catabolic
process that degrades damaged organelles and aggregated proteins, serves as a survival
mechanism against cellular stress [5–8]. Relevant to the fibrotic response in IPF, autophagy
also promotes phenotype conversion of myofibroblasts [9] with elevated levels of ECM
proteins [10]. The unfolded protein response (UPR) is an indicator of endoplasmic reticulum (ER) stress, and autophagy is a mechanism by which ER stress may be resolved
in the cell; however, sustained ER stress leads to apoptosis mediated by the activation
of caspase proteases [11]. Apoptosis dysregulation is important in the pathogenesis of
pulmonary fibrosis and can contribute to disease progression [12], and it has also been
implicated in alveolar epithelial cell pathology in individuals with lung fibrosis exposed to
thoracic irradiation [13].
UPR markers are detected in fibroblasts and lung tissues of IPF patients, indicating
a relationship between UPR and IPF [14,15]. Although markers of UPR are elevated in
fibroblasts from IPF patients, autophagy markers are lower in these cells compared to
fibroblasts from non-IPF patients [16]. Others have also reported impaired autophagy flux
in IPF lungs [17,18]. However, despite the lower autophagy activity, both autophagy and
UPR appear to be necessary for TGFβ1-induced pro-fibrotic response in IPF fibroblasts [16].
This illustrates the complex interactions among the fundamental cell stress responses
necessary to regulate lung physiological function.
Cross-talk between these mechanisms has been proposed [19–23], where unresolved
UPR can also induce apoptosis [24], a possible cause of the severe scarring observed in
IPF lung tissues. To our knowledge, we are the first to examine the direct association of
these three cell stress response mechanisms simultaneously (including UPR, autophagy,
and apoptosis) with lung function measures in patients with IPF. In this pilot clinical
observational and hypothesis-generating study, we test whether changes in lung tissue
expression of apoptosis, autophagy, and UPR markers correlate with the loss of lung
function in individuals with IPF. Our results highlight the physiological importance of cell
stress signaling pathways in IPF, which has led us to several new testable hypotheses. The
end result of such investigation may lead to much-needed novel therapies targeting cell
stress pathways.
2. Materials and Methods
2.1. Study Subjects
Patients from the University of California (U.C.) Davis Interstitial Lung Disease (ILD)
Clinic (IRB-approved registry, protocol number 295939) with lung-biopsy-confirmed IPF
were selected for this study. Diagnosis of IPF was based on the criteria outlined in American
Thoracic Society (ATS) guidelines [3], including independent confirmation by a pulmonary
pathologist, and all other causes of interstitial lung diseases were excluded based on a
thorough clinical evaluation. Inclusion criteria for initial entry into the ILD clinic registry
were as follows: (i) under the care of a UC Davis Internal Medicine Pulmonary Clinic
pulmonologist, (ii) a diagnosis of ILD, (iii) 18 years of age or older. We obtained de-
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identified human lung tissues from deceased IPF patients from the period 2005 to 2012
(Table 1). De-identified lung function data obtained at the U.C. Davis Pulmonary Function
Lab are also included in Table 1.
Table 1. IPF Patient Demographics and Characteristics.
ID1

ID2

ID3

ID4

ID1-4 $

Age
(deceased, yrs)

63

59

85

72

69.8 ± 11.5

Sex

M

M

F

M

White

White

White

Hispanic

FEV1 (L)

2.52 ± 0.11

2.12 ± 0.14

1.77 ± 0.10

2.16 ± 0.09

2.17 ± 0.22

FEV1%p

71.8 ± 2.6%

56 ± 3.6%

95.3 ± 3.8%

74.8 ± 2.9%

74.5 ± 10.1%

FVC (L)

3.15 ± 0.22

2.33 ± 0.18

2.39 ± 0.14

2.51 ± 0.08

2.58 ± 0.28

Ethnicity
Lung Function

$

FVC%p

69.8 ± 4.6%

46.7 ± 3.2%

93.3 ± 5.0%

67.4 ± 2.6%

68.4 ± 11.9%

FEV1/FVC

80%

90.1%

74.1%

86.1%

84.1%

RV (L)

0.77 ± 0.35

0.77 ± 0.05

1.54 ± 0.5

1.31 ± 0.19

1.10 ± 0.42

RV%p

34 ± 15.9%

34 ± 2.8%

65 ± 24.0%

57.8 ± 7.7%

48.3 ± 17.9%

TLC (L)

4.06 ± 0.28

3.14 ± 0.26

3.92 ± 0.68

3.91 ± 0.25

3.81 ± 0.45

TLC%p

59.7 ± 4.04%

43.5 ± 3.5%

79.5 ± 14.9%

62.8 ± 2.8%

61.5 ± 12.7%

DLCO

8.5 ± 1.8

6.9 ± 0.71

12.9 ± 2.7

10.5 ± 1.5

9.9 ± 2.3

31 ± 6.2%

22.5 ± 2.12%

66.5 ± 13.4%

45.9 ± 5.9%

42.8 ± 14.1%

#

UIP

UIP

UIP

UIP

-

Clinical Diagnosis

IPF

IPF

IPF

IPF

-

Comorbidities

AF, CAD,
DM, CKD

HIV/AIDS,
BPH, SCC
(rectal)

HTN, AV
dis, MV dis.,
RBBB, TAH

GERD, HPL,
PVD, AF,
Divrt, TIA

DLCO%p
Lung Pathology

$ noted as mean ± SD. # Based on wedge lung biopsy. Abbrev. M (male), F (female), L (liters), %p (percent
predicted), FEV1 (forced expiratory volume in the first second), FVC (forced vital capacity), RV (residual volume),
TLC (total lung capacity), DLCO (diffusion capacity of carbon monoxide), UIP (usual interstitial pneumonitis),
IPF (idiopathic pulmonary fibrosis), AF (atrial fibrillation), CAD (coronary artery disease), DM (diabetes mellitus), CKD (chronic kidney disease), HIV/AID (human immunodeficiency virus/acquired immunodeficiency
syndrome), BPH (benign prostatic hypertrophy), SCC (squamous cell carcinoma), HTN (hypertension), AV (aortic
valve), MV (mitral valve), dis. (disease), RBBB (right bundle branch block), TAH (total abdominal hysterectomy), GERD (gastroesophageal reflux disease), HPL (hyperlipidemia), PVD (peripheral vascular disease), Divrt.
(diverticulosis), TIA (transient ischemic attack).

The comparative non-IPF lung tissues were obtained from patients undergoing lung
resection surgery for lung cancer in 2010 at the University of Manitoba, Department of
Thoracic Surgery (approved by the Human Research Ethics Board, protocol HS14752
(H2002:150)). These non-IPF lung tissue slides were of peripheral lung specimens from
tumor-free, non-involved tissues, independently confirmed by a pulmonary pathologist.
Patient characteristics and lung function data are also provided in Table 2.
2.2. Immunofluorescence Immunohistochemistry
H&E staining was performed using 4 µm sections, while immunostaining was performed using primary antibodies for LC3β (Proteintech 18725-1-AP), cleaved caspase-3
(CST #9661), BiP (ab21685, Abcam), and XBP1 (ab37152, Abcam). Alexa-Fluor-conjugated
antibodies (Molecular Probes) and DAPI were used to stain the nuclei. Images were captured and analyzed in a blinded fashion using a Nikon confocal microscope, keeping
both laser intensity and detector sensitivity settings constant, and analyzed using ImageJ
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software [25]. For LC3β, we measured the puncta as representative of autophagosomes
that confirm autophagy flux.
Table 2. Non-IPF Patient Demographics and Characteristics.
ID1

ID2

ID3

ID1-3 $

Age (yrs)

76

79

73

76 ± 3

Sex

M

M

M

-

Smoking Status
(pack-years)

60 *

30 @

45 @

FEV1 (L)

1.86

2.28

3.07

2.40 ± 0.61

FEV1%p

65%

78%

99%

80.67 ± 17.2%

FVC (L)

2.85

3.34

3.71

3.3 ± 0.43

FEV1/FVC

65%

68%

83%

72 ± 9.6%

Diagnosis based
on PFT

Moderate
Obstructive
Disease

Mild Obstructive
Disease

Normal

Classification

Stage II

Stage II

N/A

Tumor

Lung Cancer

Lung Cancer

Lung Cancer

Lung Function $

COPD GOLD

$

@

noted as mean ± SD. * Current smoker; Ex-smoker; Abbrev. M (male), F (female), L (liters), %p (percent
predicted), FEV1 (forced expiratory volume in the first second), FVC (forced vital capacity), COPD (chronic
obstructive pulmonary disease), GOLD (Global Initiative for Chronic Obstructive Lung Disease), PFT (pulmonary
function test), N/A (not applicable).

2.3. Selection of Markers for Autophagy, Apoptosis, and the Unfolded Protein Response
We have chosen LC3β as one of the key markers of autophagosome formation based on
published literature [26,27] and our own findings [28–30]. Quantitatively, the measurement
of autophagosomes is based on the numbers of puncta stained with LC3β. Increased LC3β
puncta do not necessarily demonstrate autophagy flux but indicate the exact numbers
of autophagosomes without differentiation between formation and degradation. GRP78
(BiP) is an ER chaperon that is responsible for the docking of the three UPR sensors (IRE1,
ATF6, PERK). We have previously shown that immunohistochemical staining for BiP is
a reliable marker for the activation of UPR (16, 30). Hence, we used this approach in our
current work. Additionally, we also used XBP/sXBP to monitor the activation of the IRE
arm of UPR signaling. XBP/sXBP plays an important role in organ fibrosis, including
that of the lung [16] and the gut [31]. Further, we chose cleaved caspase-3 as an apoptosis
marker as it is the key caspase for cell death [32,33]; we have demonstrated this approach
in our previous study [30]. Of note, we did not use cleaved PARP-1 as an apoptosis marker
since PARP-1 is a marker for DNA repair mechanisms via PARylation and may, therefore,
interfere with the repair mechanism(s) in IPF [34].
2.4. Quantification of Immunofluorescence Intensity and Colocalization
We have calculated the immunofluorescence intensity and co-localization of different
markers using Image Zen software, as described previously [28]. Briefly, we created a
uniform region of interest (ROI) for each marker and quantified green or red fluorescence
intensities. Considering the total area of each ROI uniform, we calculated green/red
fluoresce intensity and were able to generate a percent value for some of the comparisons.
For measuring green and red co-localization in each ROI, we quantified the co-localization
using the merged fluorescence histograms created by Image Zen and by measuring the
intensity of yellow fluorescence in the ROI.
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2.5. Pulmonary Function Tests
Complete pulmonary function testing (PFT) was performed at the U.C. Davis PFT
Lab according to ATS/ERS Guidelines. PFT included spirometry, flow-volume loops, lung
volumes (measured by body plethysmography), and diffusion capacity. Lung function
was measured serially both before and after the diagnosis of IPF, including pre- and postbronchodilator measures. For our linear correlation analyses between cell stress markers
and lung function, PFT data within 1–1.5 years of the date of the lung tissue biopsy (i.e.,
pathological diagnosis) was used to avoid increasing time-based biases. More specifically,
these PFT data (over 1–1.5 years) straddled the date of lung biopsy, where the date of
biopsy was situated in the middle of this time range. For a chronic progressive disease
such as IPF, changes in lung function are typically slow and gradual and are, therefore,
unlikely to change significantly over the observed limited duration, thus reducing the
added variability that may accompany longer time ranges. With this approach, we were
able to justify our linear correlation analyses between cell stress protein markers (single
time point based on the date of lung biopsy) and PFT data (multiple time points over
1–1.5 years). This understanding then allows us to approximate lung function measures
similar to a single time point measure.
2.6. Statistical Analysis
Linear regression was used to assess correlations between patient-matched lung function parameters (absolute values for forced expiratory volume in the first second (FEV1),
forced vital capacity (FVC), residual volume (RV), total lung capacity (TLC), diffusion
capacity of carbon monoxide (DLCO)), and IPF lung tissue cell stress markers (BiP, XBP1,
LC3β puncta, cleaved caspase-3). Of note, the correlation plots do not all contain an equal
number of data points, which simply reflects randomly missing PFT values. We placed
greater interpretative power on the absolute values of lung function (e.g., as measured in
liters for FVC or TLC) rather than the percent-predicted values (e.g., FVC % predicted) that
are normalized to patient population norms. The absolute values for lung function are
direct measures of pulmonary physiology without the potentially confounding effects of
normalized values across larger population norms that do not necessarily reflect our rather
small, single-center cohort (Table 1).
Given that this was a proof-of-principle study focused on discovery and hypothesis
generation, we had a small sample size (four IPF lungs), and, thus, limited statistical
power. Therefore, for all linear correlation analyses involving lung function data, we
used a p-value cut-off of <0.1 to indicate statistical significance unless otherwise stated.
Confidence intervals are included in the figures, shown by the dotted curved lines flanking
the regression line. Goodness of fit was determined using R2 values. Of note, we only show
figures from those lung function analyses that are statistically significant. Non-significant
statistical correlations are not shown unless deemed relevant.
For analyses involving comparisons between cell stress markers by immunofluorescence, a p-value of <0.05 was chosen to indicate statistical significance (with two-way
alpha). The choice of this lower (and more commonly used) p-value cut-off reflects high
enough statistical power at the available sample size. We used Student’s t-test for all
statistical comparisons comprising parametric data. GraphPad Prism version 9.0.0 was
used to conduct all analyses.
3. Results
3.1. Co-Localization of Apoptosis, Autophagy, and UPR Markers in IPF Lung Tissues
Using confocal microscopy, we measured differences in the markers of apoptosis,
autophagy, and UPR in comparable regions of lung tissue from IPF patients and non-IPF
patients without lung fibrosis. We observed a significantly higher co-localization of UPR
(BiP) and apoptosis (cleaved caspase-3) markers (p < 0.001) in lung samples from IPF
subjects, including some involvement of small airways (Figure 1A,B). Conversely, the UPR
marker BiP did not co-localize with the autophagosome marker (LC3β puncta) in any
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of the tissues we assessed, including lung parenchyma and small airways (Figure 1C,D).
While the UPR maker XBP1 did co-localize with LC3β puncta (light orange color) in both
IPF and non-IPF lung samples, this was not significantly different between the patient and
control groups (Figure 1E,F). The tissue sections evaluated included lung parenchyma and
the small or terminal airways.
These results indicate that ER stress/UPR and apoptosis are concomitantly induced
in IPF lung cells. These correlative data are in agreement with our recent mechanistic
studies that demonstrated spliced-XBP1 as a driving factor for collagen production in IPF
fibroblasts (16). Interestingly, despite the non-colocalization of BiP with LC3β puncta in IPF
lungs and insignificant co-localization of XBP1 with LC3β puncta in both IPF and non-IPF
lungs, the total labeling of BiP, XBP1, LC3β puncta, and cleaved caspase-3 as independent
measures was significantly elevated in IPF lungs compared to non-IPF lungs (Figure 1G–J).
We did not use cell-specific markers to co-stain epithelial cells, fibroblasts, endothelial cells, or immune cells along with UPR, apoptosis, and autophagy markers. However, based on the immunofluorescence staining in Figure 1, we observe that epithelial
cells, sub-epithelial cells (which likely include fibroblasts), and lung parenchymal tissues
were involved.
3.2. Correlation between Cell Stress Markers and Lung Function in IPF
Our IPF lung tissue sections were obtained from IPF patients confirmed to have
restrictive physiology by PFT and biopsy-proven usual interstitial pneumonia (UIP), the
classical histopathology seen in IPF (Table 1). By comparison, our non-IPF patients served as
negative controls, as described in Table 2. FEV1 signifies changes in the volume expired in
the first second of a forced breath and is typically reduced in any significant lung pathology
that involves the airways and/or lung parenchyma. This value has significant prognostic
power in terms of overall patient health and correlates with mortality. Reductions in lung
volumes (FVC, RV, TLC) in IPF represents the presence of restrictive physiology due to
lung fibrosis. The loss in FVC and TLC has predictive power in interstitial lung diseases,
including IPF. The DLCO represents alveolar–capillary membrane function, which is also
typically reduced in IPF due to the presence of lung parenchymal fibrosis.

Figure 1. Cont.
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Figure 1. Co-localization of cell stress markers in IPF lung tissues. (A) Representative histological images of immunoflu-

Figureorescence
1. Co-localization
of cell stress markers in IPF lung tissues. (A) Representative histological
confocal microscopy of IPF and non-IPF lung tissues for cleaved caspase-3 (green), BiP (red), and DAPI (blue).
Co-localization
can
be
seen
as
a light orange
color in dotted
areas in the merged
images
(farnon-IPF
right side). (B)
IPF lungs
had for cleaved
images of immunofluorescence
confocal
microscopy
of IPF
and
lung
tissues
significantly greater co-localization of c-caspase-3 and BiP compared to non-IPF lungs (p < 0.001). (C) Representative
histological
imagesBiP
of immunofluorescence
confocal(blue).
microscopy
of non-IPF and IPF lungcan
tissues
LC3β puncta
caspase-3
(green),
(red), and DAPI
Co-localization
beforseen
as a (green),
light orange color
BiP (red), and DAPI (blue). Very little co-localization is observed in the merged images (far right side) for both non-IPF
in dotted
areas
in
the
merged
images
(far
right
side).
(B)
IPF
lungs
had
significantly
greater coand IPF lung tissues. (D) There was no statistically significant difference in co-localized BiP and LC3 puncta between IPF
localization of c-caspase-3 and BiP compared to non-IPF lungs (p < 0.001). (C) Representative
histological images of immunofluorescence confocal microscopy of non-IPF and IPF lung tissues
for LC3β puncta (green), BiP (red), and DAPI (blue). Very little co-localization is observed in the
merged images (far right side) for both non-IPF and IPF lung tissues. (D) There was no statistically
significant difference in co-localized BiP and LC3β puncta between IPF and non-IPF lungs (p = NS).
(E) Representative histological images of immunofluorescence confocal microscopy of non-IPF and
IPF lung tissues for LC3β puncta (green), XBP1 (red), and DAPI (blue). Some co-localization is
observed in the merged images (far right side) for both non-IPF and IPF lung tissues. (F) There
was no statistically significant difference in co-localized XBP1 and LC3β puncta between IPF and
non-IPF lungs (p = NS). The percentage of positive signals for BiP (G), XBP1 (H), LC3β puncta (I),
and cleaved caspase-3 (J) was measured as the ratio of areas between the region of interest and the
total image area. This was performed on all the images captured from sections for each lung tissue
for all subjects. Data were collected in triplicate, and results are represented as the overall average for
all the captured images. Note: Magnification was ×40 for images in Panels A, C, and E (scale bars
are included in each image). For statistical calculations in Panels A–F, areas with co-localization of
any two cell stress markers were calculated using ImageJ in both non-IPF and IPF lungs. The middle
horizontal line in Panels B, D, F represents the median value in each group. Results in Panels G–J
are represented as means ± SD. A p-value of <0.05 was considered statistically significant. GraphPad
Prism 9 was used for all analyses. Abbreviations: NS (not significant).
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We examined the associations between cell stress marker expression and lung function
parameters and found that greater expression (i.e., labeling by immunofluorescence) of
both XBP1% and BiP% (UPR) (Figure 2A,B) and cleaved caspase-3% (apoptosis) (Figure 2C)
in IPF lungs was associated with reduced FEV1, FVC, TLC, and RV, respectively. Conversely, greater expression of LC3β puncta% was positively correlated with increased
DLCO (Figure 2D). This suggests that both increased UPR and increased apoptosis are
independently associated with reduced lung function in IPF, as measured by FEV1, FVC,
TLC, and RV, while the presence of autophagosomes in IPF lungs is associated with higher
9 of 18
DLCO. These are important lung function parameters that also relate to the functional
capacity of IPF patients.
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We then assessed correlations between co-localized UPR, autophagy, and apoptosis
markers. We also hypothesized that co-localized markers of UPR and autophagy in IPF
lung tissues would correlate with lower lung function values, similar to our XBP1, BiP,
and cleaved caspase-3 results. However, we found that the opposite was true. Higher
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We then assessed correlations between co-localized UPR, autophagy, and apoptosis
markers. We also hypothesized that co-localized markers of UPR and autophagy in IPF
lung tissues would correlate with lower lung function values, similar to our XBP1, BiP,
and cleaved caspase-3 results. However, we found that the opposite was true. Higher
immunofluorescence of overlapping markers XBP1 and LC3β puncta was consistently
associated with significantly greater FEV1, FVC, and TLC (Figure 3A,B). Higher immunofluorescence of overlapping markers BiP and LC3β puncta was associated with significantly
increased DLCO (p = 0.0067) (Figure 3C). However, co-localized LC3β puncta and BiP
were not significantly correlated with any lung function parameters (p > 0.1) (data not
shown). There were no statistically significant correlations between overlapping markers
of BiP and cleaved caspase-3 for any lung function parameter (data not shown). These
results suggest that co-localized markers of UPR (XBP1, BiP) and autophagy (LC3β puncta)
are associated with improved lung function (increased FEV1, FVC, TLC, DLCO). Figure 4
graphically summarizes our results and describes testable hypotheses to direct future
research in this area.

Figure 3. Correlations between co-localized UPR (XBP1, BiP) and autophagy (LC3β puncta) markers and lung function in
IPF. (A) Co-localized XBP1 and LC3β puncta were positively correlated with FEV1 (* p = 0.067, R2 = 0.36), FVC (* p = 0.099,
R2 = 0.30), and TLC (* p = 0.013, R2 = 0.67). (B) Co-localized LC3β puncta and XBP1 were positively correlated with FEV1
(* p = 0.02, R2 = 0.51), FVC (* p = 0.046, R2 = 0.41), and TLC (*p = 0.027, R2 = 0.59). (C) Co-localized BiP and LC3β puncta
were positively correlated with DLCO (* p = 0.0067, R2 = 0.58). Confidence intervals are included, shown by the dotted
curved lines flanking the regression line. Linear regression analyses were performed using GraphPad Prism 9. Lung
volumes (FEV1, FVC, TLC) were measured in liters, and the diffusion capacity of carbon monoxide (DLCO) was measured
in mL/mmHg/min.
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Figure 4. Five testable hypotheses regarding the relative contributions of UPR, apoptosis, and
autophagy to pulmonary fibrosis and lung function changes. The confocal and linear correlation data
presented in Figures 1–3 highlight critical connections linking cell stress biology, lung fibrosis, and the
resultant lung function changes in patients that lead to debilitating symptoms. (A) Co-localization
of cleaved caspase-3 and BiP was significantly greater in IPF lungs than non-IPF lungs, but the
causal link to lung fibrosis and lung function remains unknown. (B) UPR markers XBP1 and BiP and
apoptosis marker cleaved caspase-3 were independently associated with lower lung function in IPF,
but the cross-talk between these pathways remains incompletely understood. (C) The increase in
autophagosome formation (i.e., increased expression of LC3β puncta) could represent either active
autophagy flux or the inhibition of autophagy flux. Our data show that autophagy is definitely
involved and correlates with improvement in the lung function parameter (i.e., improvement in
DLCO); however, the directionality of autophagy remains unknown. (D) Co-localization of UPR
(XBP1, BiP) and autophagy (LC3β puncta) was associated with higher lung function; however,
the mechanism of this observation is not yet known. Our data suggest that within the context of
active UPR in IPF lungs, the presence of autophagy changes the consequence of UPR and leads
to higher lung function. Whether this occurs via the inhibition or activation of autophagy flux
remains unknown. The results from Figures 1 and 2, depicted graphically in Panels A and B, lead to
Hypothesis 1. Cross-talk and dysregulation between apoptosis and UPR pathways cause lung fibrosis, which
leads to progressive loss of lung function. The results from Figures 2 and 3, depicted graphically in Panels
C and D, lead to the following four hypotheses: Hypothesis 2a. Autophagy inhibition reduces lung
fibrosis, which, in turn, preserves or improves lung function. Hypothesis 2b. Autophagy activation reduces
lung fibrosis, which, in turn, preserves or improves lung function. Hypothesis 3a. Within the context of
active UPR (XPB1 and BiP), the inhibition of autophagy reduces lung fibrosis, which improves lung function.
Hypothesis 3b. Within the context of active UPR (XPB1 and BiP), the activation of autophagy reduces lung
fibrosis, which improves lung function. Note: Dotted line arrows indicate multiple intervening steps not
shown. Solid line arrows indicate a direct effect of lung fibrosis on lung function.
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We also conducted additional analyses to corroborate our linear correlation results. As
described in greater detail in the Supplementary Material and Figure S1, we re-analyzed a
subset of the data shown in Figures 2 and 3. After randomly matching cell stress marker
expression with lung function data, we repeated linear correlations. The results obtained
were similar to the original analyses in Figures 2 and 3. Notably, on repeat analysis after
random allocations, the XBP1% and FEV1 negative correlation was stronger and became
statistically significant (p = 0.084, R2 = 0.33) (Figures S1A and S2A).
4. Discussion
Taken together, our results suggest that UPR, autophagy, and apoptosis protein expression markers are significantly increased in IPF compared to non-IPF lungs. Moreover, in
IPF lungs, we observed significantly increased co-localization of BiP and cleaved caspase-3
compared to non-IPF lungs (Figure 1A), which points toward a co-active UPR and apoptotic
signaling pathway in IPF. These novel findings of increased UPR and apoptosis markers in
IPF lungs also correlated with changes in lung function. We discovered that UPR (XBP1,
BiP) and apoptosis (cleaved caspase-3) were each associated with a reduction in FEV1, FVC,
TLC, and RV. In contrast, increased expression of either LC3β puncta or co-localized LC3β
puncta and UPR markers (XBP1, BiP) were associated with increased DLCO or increased
FEV1, FVC, TLC, and DLCO, respectively. The co-existence of these cell stress pathways in
IPF pathogenesis and the link to changes in lung function (a key clinical determinant) are
unique findings.
Cellular phenotype is tightly regulated via autophagy and UPR in lung epithelial
and mesenchymal cells [35,36]. For example, TGFβ1 has been shown to induce changes in
autophagic flux (decreased LC3β puncta expression) and increased cellular senescence in
IPF lung fibroblasts [10,37]. Autophagy induction also controls UPR-induced senescence
in bronchial epithelial cells, while autophagy inhibition blocks this [7]. We also know
that nintedanib (a multiple tyrosine kinase inhibitor) downregulates ECM production
and promotes autophagy in IPF fibroblasts while inhibiting TGFβ1 signaling, which confirms the role of autophagy in the regulation of IPF fibroblasts (synthetic phenotype) [38].
Conversely, we previously reported that TGFβ1-induced ECM protein production was significantly higher in IPF lung fibroblasts compared with non-IPF donors [16]. While TGFβ1
concomitantly induced autophagy and profibrotic signaling, leading to the accumulation of
ECM proteins in vitro, autophagy-related signaling was significantly lower in lung fibroblasts from IPF subjects compared to non-IPF fibroblasts. Further, inhibition of autophagy
signaling prevented TGFβ1-induced ECM production by lung fibroblasts obtained from
both non-IPF and IPF donors [16]. Interestingly, TGFβ1 induced UPR markers only in IPF
lung fibroblasts, suggesting a greater-than-anticipated role of ER stress and UPR signaling
in lung fibrosis.
Our results bring a level of nuance not always present in in vitro or animal in vivo
studies because we relate the complex existence of cell stress protein markers in human IPF
lungs to lung function for those same subjects. Putting our previous results into context,
we learned that while there is a significant increase in the accumulation of autophagosomes (LC3β puncta) in IPF lungs compared to control non-IPF lung tissues (which shows
dysregulation of autophagy flux in IPF lungs) (Figure 1I), the presence of LC3β puncta
alone (Figure 2D), or when LC3β puncta are co-localized with UPR markers (Figure 3), is
associated with improved lung function. Of note, the presence of LC3β puncta can represent either inhibition or increase in “autophagy flux” (Figure 4C). Our previous studies
indicate that (i) autophagy is necessary for the fibrotic response in IPF fibroblasts, and (ii)
autophagy inhibition reduces this fibrotic response in lung fibroblasts [16]. Combining
these two observations would suggest that in human IPF, there is endogenous inhibition of
autophagy through mechanisms that may be reliant on changes in cellular ADP/ATP ratios
or a potential cross-talk between apoptosis and autophagy (Bcl2-Beclin-1) [38–41] that,
in turn, leads to reduced fibrosis and thus, improved (or better preserved) lung function
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(Figure 4C). This is an interesting and new hypothesis that can be tested, which could shed
new insights into the role of autophagy in IPF.
We believe such mechanisms could be controlling the cellular phenotype (epithelialto-mesenchymal transition), cellular secretome, and cellular responses to apoptosis, which
favors the downregulation of pro-fibrotic signaling to prevent further deterioration of lung
function in IPF [42]. Despite the observation that alveolar epithelial cells in IPF appear to
be damaged or injured with high rates of apoptosis, the actual causative factor(s) are not
entirely known. Evidence is now emerging to support the association between alveolar
epithelial cell apoptosis and lung fibrosis. Although the mechanisms that cause alveolar
epithelial cell death are not completely understood, it is known that TGFβ1 plays an
important role as a potent inducer of apoptosis in alveolar epithelial cells, predominantly
by modulating Fas-mediated apoptosis via caspase-8 activation and downregulation of
p21 [43]. It has also emerged that TGFβ1 can activate p38/MAPK and early growth
response gene (Egr)-1 in a SMAD-dependent and SMAD-independent manner, leading to
the induction of pro-apoptotic signaling molecules such as caspase-3 [44,45]. Further, while
inducing apoptosis, TGFβ1 promotes the imbalance of Blc family members by stimulating
Bax and Bid in the murine lung. TGFβ1–mediated SMAD3 signaling is required for the
upregulation of death-associated protein kinase, which is essential for TGFβ1–induced
apoptosis of lung epithelial cells. Collectively, TGFβ1 can induce both canonical and
non-canonical signaling to promote alveolar epithelial cell apoptosis and lung fibrosis.
Our data support the newly emerging concept in the field that lung function changes
in IPF are unlikely to be attributed to a single perturbed cell stress marker in isolation but
are more likely the result of a complex network of cell stress events leading to disease.
One alternative interpretation of our results is that the combination of increased UPR and
autophagy is necessary for maintaining homeostatic lung function in IPF. However, we
cannot invoke causation given our study design; therefore, additional research is warranted
to further dissect the underlying mechanisms and their impact on lung function at different
stages of disease and among various types of IPF.
Our correlation analysis between cell stress markers and lung function in IPF subjects
suggests a more complex interaction. We previously reported that the UPR is an important
driver of TGFβ1-induced collagen production in primary human lung IPF fibroblasts
(16). However, to our knowledge, no one has directly linked measures of UPR markers
with lung function in patients with IPF. We found that both increased UPR markers XBP1
and BiP are associated with decreased lung function (FEV1, FVC, TLC) (Figure 2A,B).
Interestingly, these correlations are the exact opposite when UPR is co-localized with the
autophagy marker LC3β puncta (Figure 3), thus highlighting the expected complexity
inherent to these cell stress signaling pathways. BiP is the upstream chaperon that inhibits
PERK (protein kinase R (PKR)-like endoplasmic reticulum kinase), IRE1 (inositol-requiring
enzyme 1), and ATF6 (activating transcription factor 6) chaperons via direct interaction in
non-stressed conditions [20,46,47]. Therefore, BiP expression is representative of the overall
activation of UPR and the potential involvement of all three arms of this pathway [48].
IRE1 has both kinase and RNAse activity, and its RNAse activity is responsible for the
splicing of XBP1 into “spliced XPB1” (XBP1s) [49]. XBP1s is a transcription factor that
is responsible for cell proliferation, endoplasmic reticulum (ER)-associated degradation
(ERAD), and lipid biosynthesis [20]. On the other hand, UPR is also connected to autophagy
flux via PERK and the IRE1 arm through the regulation of LC3β expression. UPR can also
regulate apoptosis through modulation of Bcl2 family proteins and CHOP expression [20].
Therefore, we can conclude that changes in BiP expression can potentially be representative
of the general regulation of UPR while changes in XBP1 expression only represent the IRE1
arm. Further investigation into how these pathways interact to impact lung cell physiology
and, in turn, lung function, symptoms, and patients’ functional capacity is warranted.
The transcription factor XBP1s is important in fibrosis, as shown in several previous
experimental models [50,51]. XBP1s is responsible for inflammatory-mediated peritoneal
fibrosis in peritoneal dialysis, and the IRE1 endonuclease inhibitor STF083010 inhibits
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this effect [52]. On the other hand, XBP1 regulates liver fibrosis via the transport and
Golgi organization-1 (TANGO1)-collagen axis [53] and the regulation of ATG7-dependent
autophagy in hepatic stellate cells [54]. In addition, IRE1 inhibitor 4µ8C blocks liver and
skin fibrosis via the IRE1–XBP1 axis in mice [55]. Our recent report also showed that
targeting the IRE1 RNAse component inhibits TGFβ1-induced ECM deposition in IPF
fibroblasts [16]. Taken together, XBP1 appears to be an important component of UPR in the
regulation of fibrosis in multiple organs, including the lung.
Except for an isolated negative correlation with RV (Figure 2C), cleaved caspase-3,
when co-localized with BiP, did not reveal any significant correlations with other lung function measures. While other studies have reported apoptosis activation in airway epithelial
cells in human IPF lungs [56,57], which is associated with insufficient and dysregulated
repair mechanisms, our results suggest that increased apoptosis in IPF lungs may not
play a major role in determining lung function (at least with respect to the most relevant
PFT measures pertinent to IPF, i.e., FEV1, FVC, TLC, DLCO). In addition, few in vitro and
in vivo studies show that dysregulated apoptosis in myofibroblasts leads to lung tissue
fibrosis, including in mouse models of TGFβ-induced pulmonary fibrosis [58]. Conversely,
nintedanib, an FDA-approved anti-fibrotic drug for the treatment of IPF, which delays
the decline in lung function (i.e., preserves FVC), can induce apoptosis in lung fibroblasts,
leading to decreased proliferation and reduced production of ECM proteins such as collagen [59,60]. One explanation for this discrepancy could be differences in experimental
models (human tissue vs. cells/vs. mouse models of lung fibrosis). In addition, the
complexity of how these cell stress pathways converge in human IPF, which has evolved
over many years, provides an ongoing challenge to our understanding.
Our study has significant limitations, including the small sample size and reduced
statistical power, as well as the observational study design that does not permit us to
determine causation. While our design allows for hypothesis generation, the small sample
size precludes any generalizability to IPF or other forms of lung fibrosis. However, our
results highlight the potentially critical role of cellular ER stress/UPR, apoptosis, and
autophagy as convergent pathways and their impact on lung function and, therefore, their
potential impact on symptoms and IPF disease progression. Further studies are needed
to determine whether inhibition of UPR and/or inhibition or induction of autophagy
pathways can preserve lung function in patients with IPF. Another potential limitation of
our study design is the domain of lung function measures collected over a focused time
period (1–1.5 years), which allowed correlations to cell stress markers measured at a single
time point (i.e., date of lung biopsy). We address this above in the Pulmonary Function
Tests and Statistical Analysis sections; however, we cannot fully exclude potentially hidden
biases with unknown confounders. However, our independent analysis, provided in
the supplemental material (Figure S1), addresses one potential confounding effect. This
additional analysis showed that our original allocations and analysis were valid in terms
of the linear correlation outcomes and directions of these correlations between cell stress
markers and lung function parameters.
In summary, there appears to be an intriguing paradox or disconnect between the observed increases in cell stress markers in IPF lung tissues and the functional consequences
of this increased expression with respect to lung function. While single markers in isolation
correlate with reduced lung function (XBP1, BiP, cleaved caspase-3) when viewed in conjunction with autophagy, we observed the opposite correlation of improved lung function
(Figure 4). We speculate that the dynamic cross-talk occurring between different lung cells
in IPF that simultaneously run all three cell stress programs yields functional consequences,
i.e., changes in lung function, that cannot be predicted by simply investigating these cell
stress pathways in static lung tissues or as single markers in isolation. As a result, we
propose five independent hypotheses worthy of further testing, as indicated in Figure 4.
As a further caveat, all three cell stress pathways must be investigated concomitantly in
any experimental system to properly understand their dynamic interactions. This is the
least we can do regarding these critical cell stress/cell fate pathways to gain the depth
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of understanding required to impact the fibrosis field. This idea and approach also has
clinical relevance because there are inhibitors of UPR proteins as well as both inhibitors
and inducers of autophagy [61,62], both of which (or in combination) may prove to be
useful in the future treatment of IPF.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/cells10071642/s1, Figure S1: Correlations of Cell Stress Markers and Lung Function after
Random Assignments of Data and Figure S2: Representative Lung Histopathology Images of IPF
and Non-IPF Subjects.
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